Compounds > Thieno[3,2-b]thiophene-2-carboxylic acid
Page last updated: 2024-12-09

Thieno[3,2-b]thiophene-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID660319
CHEMBL ID1173787
CHEBI ID195115
SCHEMBL ID335232

Synonyms (40)

Synonym
c7h4o2s2
STL356208
smr000034684
IDI1_017992
EU-0047810
MLS000036934 ,
MAYBRIDGE3_006605
SR-01000001856-2
NCGC00019959-01
HMS1449M05
AKOS001475971
CHEMBL1173787
thieno[3,2-b]thiophene-5-carboxylic acid
CHEBI:195115
thieno[3,2-b]thiophene-2-carboxylic acid
NCGC00019959-02
EN300-51369
1723-27-9
HMS2316P13
CCG-51876
thieno[3,2-b]thiophene-2-carboxylicacid
FT-0633796
FS-1744
thiopheno[3,2-b]thiophene-2-carboxylic acid
SCHEMBL335232
thienothiophene carboxylic acid
T3156
bdbm48329
5-thieno[3,2-b]thiophenecarboxylic acid
cid_660319
thieno[3,2-b]thiophene-2-carboxylic acid, aldrichcpr
nuk ,
DTXSID90349773
mfcd00115174
J-010811
Q27463950
F12380
CS-0155512
SY050475
Z666140572

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" A virtual fragment screen was undertaken of the enzyme to discover starting points for the development of inhibitors which are likely to have appropriate physicochemical properties for an orally bioavailable compound."( Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
Alibu, VP; Barrett, MP; Brenk, R; Campbell, G; Gilbert, IH; Ruda, GF, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thienothiophene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency19.95260.28189.721235.4813AID2326
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.01585.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency0.01585.804836.130665.1308AID540263
gemininHomo sapiens (human)Potency4.61090.004611.374133.4983AID624296
Guanine nucleotide-binding protein GHomo sapiens (human)Potency30.30011.995325.532750.1187AID624287; AID624288
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency22.10611.000010.475628.1838AID1457; AID901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen receptor beta isoform 1Homo sapiens (human)IC50 (µMol)50.00001.91098.316518.7976AID733
G-protein coupled receptor 35Homo sapiens (human)IC50 (µMol)57.00000.03001.39804.6600AID630382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 35Homo sapiens (human)EC50 (µMol)42.40000.00202.50079.8000AID630439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
cytoskeleton organizationG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationG-protein coupled receptor 35Homo sapiens (human)
chemokine-mediated signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityG-protein coupled receptor 35Homo sapiens (human)
negative regulation of neuronal action potentialG-protein coupled receptor 35Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 35Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 35Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1390970Inhibition of Mycobacterium tuberculosis IMPDH deltaCBS mutant assessed as reduction in NADH production using IMP as substrate preincubated for 5 mins followed by substrate addition measured for 32 mins in presence of NAD+2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.
AID1390975Inhibition of Mycobacterium tuberculosis IMPDH deltaCBS mutant assessed as reduction in NADH production at 1 mM using IMP as substrate preincubated for 5 mins followed by substrate addition measured for 32 mins in presence of NAD+2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.
AID630442Agonist activity at GPR35 in human HT-29 cells after 1 hr by dynamic mass redistribution assay in presence of 64 uM GPR35 antagonist SPB051422011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID630386Agonist activity at GPR35 in human U20S cells expressing beta-lactamase and GPR35-GA14-VP16 transcription factor fusion protein assessed as transcriptional activation after 5 hrs by tango beta-arrestin translocation reporter assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID630439Agonist activity at GPR35 in human HT-29 cells after 1 hr by dynamic mass redistribution assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID492274Inhibition of Trypanosoma brucei 6PGDH expressed in Escherichia coli at 200 uM by spectroscopy2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID630382Agonist activity at GPR35 in human HT-29 cells assessed as desensitization of 1 uM zaprinast-induced DMR after 1 hr by dynamic mass redistribution assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID630387Agonist activity at GPR35 in human U20S cells expressing beta-lactamase and GPR35-GA14-VP16 transcription factor fusion protein assessed as transcriptional activation after 5 hrs by tango beta-arrestin translocation reporter assay relative to zaprinast2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID630381Agonist activity at GPR35 in human HT-29 cells after 1 hr by dynamic mass redistribution assay relative to zaprinast2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID1390971Mixed-type inhibition of Mycobacterium tuberculosis IMPDH deltaCBS mutant assessed as reduction in NADH production preincubated for 5 mins followed by substrate IMP addition at increasing concentration measured for 32 mins in presence of constant concentr2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.
AID630441Agonist activity at GPR35 in human HT-29 cells after 1 hr by dynamic mass redistribution assay in presence of GPR35 antagonist SPB051422011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
AID1390973Uncompetitive inhibition of Mycobacterium tuberculosis IMPDH deltaCBS mutant assessed as reduction in NADH production preincubated for 5 mins followed by substrate IMP addition at a constant concentration measured for 32 mins in presence of increasing con2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-naphthol
1-naphthol: RN given refers to parent cpd. 1-naphthol : A naphthol carrying a hydroxy group at position 1.. hydroxynaphthalene : Any member of the class of naphthalenes that is naphthalene carrying one or more hydroxy groups.		2.1710naphtholgenotoxin;
human xenobiotic metabolite
phenylmethanesulfonic acid
phenylmethanesulfonic acid: RN given refers to parent cpd		2.0510
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		2.1710naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
2,7-dihydroxynaphthalene
[no description available]		2.1710
cysteic acid
Cysteic Acid: Beta-Sulfoalanine. An amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.. cysteic acid : An amino sulfonic acid that is the sulfonic acid analogue of cysteine.		2.0510alanine derivative;
amino sulfonic acid;
carboxyalkanesulfonic acid;
cysteine derivative;
non-proteinogenic alpha-amino acid		animal metabolite
4(5)-phenylimidazole
4(5)-phenylimidazole: tautomeric cpd; cytochrome P450 14alpha-sterol demethylase, CYP51 antagonist		2.1710
3-cyanoindole
[no description available]		2.1710
4-(1h-imidazol-1-yl) aniline
[no description available]		2.1710
4-phospho-d-erythronohydroxamic acid
[no description available]		2.0510
4-phosphoerythronate
4-phosphoerythronate: inhibits ribose-5-phosphate isomerase. 4-phospho-D-erythronic acid : The D-enantiomer of 4-phosphoerythronic acid.		2.05104-phosphoerythronic acidEscherichia coli metabolite;
mouse metabolite
cid-2745687
[no description available]		2.0610
zaprinast
zaprinast: anaphylaxis inhibitor; structure		2.0610triazolopyrimidines
ConditionIndicatedRelationship StrengthStudiesTrials
African Sleeping Sickness
[description not available]		02.0510
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		02.0510